KALV
Income statement / Annual
Last year (2024), KalVista Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, KalVista Pharmaceuticals, Inc.'s net income was -$126.64 M.
See KalVista Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
04/30/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$12.69 M
|
$12.69 M
|
$16.13 M
|
$8.39 M
|
$1.50 M
|
$2.13 M
|
$1.80 M
|
| Cost of Revenue |
$86.17 M |
$802,000.00 |
$743,000.00 |
$651,000.00 |
$40,194.00 |
$35,021.00 |
$18,237.00 |
$12,666.00 |
$14,661.00 |
$8,285.00 |
| Gross Profit |
-$86.17 M |
-$802,000.00 |
-$743,000.00 |
$12.04 M |
$12.65 M |
$16.09 M |
$8.38 M |
$1.49 M |
$2.12 M |
$1.80 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0.95 |
1 |
1 |
1 |
0.99 |
0.99 |
1 |
| Research and Development
Expenses |
$86.17 M
|
$80.28 M
|
$70.17 M
|
$41.29 M
|
$40.19 M
|
$35.02 M
|
$18.24 M
|
$12.67 M
|
$14.66 M
|
$8.29 M
|
| General & Administrative
Expenses |
$54.28 M
|
$30.60 M
|
$26.45 M
|
$16.64 M
|
$13.03 M
|
$10.93 M
|
$8.86 M
|
$11.18 M
|
$2.65 M
|
$1.61 M
|
| Selling & Marketing
Expenses |
-$816,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$54.28 M
|
$30.60 M
|
$26.45 M
|
$16.64 M
|
$13.03 M
|
$10.93 M
|
$8.86 M
|
$11.18 M
|
$2.65 M
|
$1.61 M
|
| Other Expenses |
-$86.17 M |
$15.64 M |
$14.72 M |
$9.93 M |
$9.83 M |
$7.68 M |
$4.39 M |
$2.33 M |
$2.03 M |
$844,000.00 |
| Operating Expenses |
$54.28 M |
$110.87 M |
$96.61 M |
$57.92 M |
$53.22 M |
$45.95 M |
$27.10 M |
$23.84 M |
$17.31 M |
$9.89 M |
| Cost And Expenses |
$140.45 M |
$110.87 M |
$96.61 M |
$57.92 M |
$53.22 M |
$45.95 M |
$27.10 M |
$23.84 M |
$17.31 M |
$9.89 M |
| Interest Income |
$0.00 |
$2.23 M |
$1.09 M |
$903,000.00 |
$1.83 M |
$1.40 M |
$82,000.00 |
$36,000.00 |
$50,000.00 |
$19,000.00 |
| Interest Expense |
$0.00 |
-$17.96 M |
$1.09 M |
$0.00 |
$0.00 |
-$9.18 M |
-$2.90 M |
-$3.74 M |
-$3.75 M |
-$863,000.00 |
| Depreciation &
Amortization |
$816,000.00
|
$802,000.00
|
$743,000.00
|
$651,000.00
|
$525,000.00
|
$378,000.00
|
$180,000.00
|
$40,000.00
|
$133,000.00
|
$38,000.00
|
| EBITDA |
-$139.63 M
|
-$110.24 M
|
-$94.51 M
|
-$58.23 M
|
-$39.65 M
|
-$29.49 M
|
-$16.95 M
|
-$23.67 M
|
-$16.81 M
|
-$8.05 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-4.59 |
-3.12 |
-1.83 |
-2.02 |
-15.74 |
-7.88 |
-4.46 |
| Operating Income Ratio
|
0
|
0
|
0
|
-4.56
|
-3.19
|
-1.85
|
-2.23
|
-14.85
|
-7.12
|
-4.48
|
| Total Other
Income/Expenses Net |
$13.80 M
|
$17.96 M
|
$14.27 M
|
$11.68 M
|
$11.29 M
|
$7.73 M
|
$2.82 M
|
$3.70 M
|
$3.70 M
|
$844,000.00
|
| Income Before Tax |
-$126.64 M |
-$92.91 M |
-$82.34 M |
-$46.24 M |
-$29.24 M |
-$20.69 M |
-$15.81 M |
-$18.60 M |
-$11.44 M |
-$7.23 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-3.64
|
-2.3
|
-1.28
|
-1.88
|
-12.37
|
-5.36
|
-4.01
|
| Income Tax Expense |
-$8.45 M |
-$18.05 M |
-$13.83 M |
-$1.75 M |
-$124,000.00 |
$124,000.00 |
-$1.33 M |
-$5.11 M |
-$5.41 M |
-$863,000.00 |
| Net Income |
-$126.64 M |
-$74.85 M |
-$68.51 M |
-$44.49 M |
-$29.12 M |
-$20.82 M |
-$15.81 M |
-$18.60 M |
-$11.44 M |
-$7.23 M |
| Net Income Ratio |
0 |
0 |
0 |
-3.51 |
-2.29 |
-1.29 |
-1.88 |
-12.37 |
-5.36 |
-4.01 |
| EPS |
-3.44 |
-2.68 |
-2.8 |
-2.33 |
-1.64 |
-1.38 |
-1.53 |
-1.92 |
-2.4 |
-6.17 |
| EPS Diluted |
-3.44 |
-2.68 |
-2.8 |
-2.33 |
-1.64 |
-1.38 |
-1.53 |
-1.92 |
-2.4 |
-6.17 |
| Weighted Average Shares
Out |
$36.79 M
|
$27.89 M
|
$24.47 M
|
$19.09 M
|
$17.75 M
|
$15.08 M
|
$10.32 M
|
$9.71 M
|
$4.77 M
|
$1.17 M
|
| Weighted Average Shares
Out Diluted |
$36.79 M
|
$27.89 M
|
$24.47 M
|
$19.09 M
|
$17.75 M
|
$15.08 M
|
$10.32 M
|
$9.71 M
|
$4.77 M
|
$1.17 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
